Atara Biotherapeutics Files 8-K
Ticker: ATRA · Form: 8-K · Filed: Jan 16, 2025 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-condition, operations
TL;DR
Atara Bio filed an 8-K on Jan 16, 2025, updating on financials.
AI Summary
On January 16, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with other events and financial statements. No specific financial figures or significant events beyond the filing itself were detailed in the provided text.
Why It Matters
This filing indicates that Atara Biotherapeutics is providing an update on its financial condition and operations to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain specific negative or positive news that would immediately alter risk perception.
Key Players & Entities
- Atara Biotherapeutics, Inc. (company) — Registrant
- January 16, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Atara Biotherapeutics?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as other events and financial statements.
On what date was this 8-K report filed or effective?
The report was filed as of January 16, 2025, and the date of the earliest event reported is also January 16, 2025.
What is Atara Biotherapeutics' principal executive office address?
Atara Biotherapeutics' principal executive offices are located at 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, California, 91320.
What is the telephone number for Atara Biotherapeutics?
The Registrant's telephone number, including area code, is (805) 623-4211.
What is Atara Biotherapeutics' Standard Industrial Classification (SIC) code?
Atara Biotherapeutics' SIC code is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-01-16 16:05:26
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Mar
Filing Documents
- atra-20250116.htm (8-K) — 44KB
- atra-ex99_1.htm (EX-99.1) — 30KB
- 0000950170-25-006191.txt ( ) — 192KB
- atra-20250116.xsd (EX-101.SCH) — 24KB
- atra-20250116_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. In connection with the press release described in Item 8.01 below, on January 16, 2025, Atara Biotherapeutics, Inc. (the "Company") announced the Company's cash, cash equivalents and short-term investments as of December 31, 2024. The preliminary estimate is based on currently available information and does not present all necessary information for a complete understanding of the Company's financial condition as of December 31, 2024 or the Company's results of operations for the fourth quarter or year ended December 31, 2024.
01 Other Events
Item 8.01 Other Events. On January 16, 2025, the Company issued a press release titled "Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO (tabelecleucel)." A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference into this Item 8.01.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated January 16, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atara Biotherapeutics, Inc. Date: January 16, 2025 By: /s/ AnhCo Nguyen AnhCo Nguyen, Ph.D. President and Chief Executive Officer